Ignite Creation Date:
2024-05-05 @ 4:43 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00309556
Status:
COMPLETED
Last Update Posted:
2011-12-30
First Post:
2006-03-31
Brief Title:
Randomized Neoadjuvant Study of Epirubicin and Docetaxel WithWithout Capecitabine in Early Breast Cancer
Sponsor:
Austrian Breast Colorectal Cancer Study Group
Organization:
Austrian Breast Colorectal Cancer Study Group
Organization Data
Organization:
Austrian Breast Colorectal Cancer Study Group
Class:
NETWORK
Study ID:
ABCSG-24
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Austrian Breast Colorectal Cancer Study Group
Lead Sponsor Class:
NETWORK
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Sanofi | INDUSTRY |
| Amgen | INDUSTRY |
| Ebewe Pharma GmbH | UNKNOWN |
| Hoffmann-La Roche | INDUSTRY |